Scinovex
reviewTop 1% cited

Overdiagnosis in Cancer

JNCI Journal of the National Cancer Institute · 2010 · Vol. 102(9) · pp. 605–613
H. Gilbert WelchWilliam C. Black

Abstract

This article summarizes the phenomenon of cancer overdiagnosis-the diagnosis of a "cancer" that would otherwise not go on to cause symptoms or death. We describe the two prerequisites for cancer overdiagnosis to occur: the existence of a silent disease reservoir and activities leading to its detection (particularly cancer screening). We estimated the magnitude of overdiagnosis from randomized trials: about 25% of mammographically detected breast cancers, 50% of chest x-ray and/or sputum-detected lung cancers, and 60% of prostate-specific antigen-detected prostate cancers. We also review data from observational studies and population-based cancer statistics suggesting overdiagnosis in computed tomography-detected lung cancer, neuroblastoma, thyroid cancer, melanoma, and kidney cancer. To address the problem, patients must be adequately informed of the nature and the magnitude of the trade-off involved with early cancer detection. Equally important, researchers need to work to develop better estimates of the magnitude of overdiagnosis and develop clinical strategies to help minimize it.

Lung Cancer Diagnosis and TreatmentGlobal Cancer Incidence and ScreeningRadiomics and Machine Learning in Medical ImagingOverdiagnosisMedicineCancerLung cancerDiseasePopulationObservational studyBreast cancerProstate cancerOncology

MeSH terms

BiopsyBreast NeoplasmsFemaleHumansLung NeoplasmsMaleMammographyMass ScreeningNeoplasm StagingNeoplasmsProstatic NeoplasmsThyroid NeoplasmsBiomarkers, TumorUnited StatesRandomized Controlled Trials as Topic
Citations
1,567
FWCI
86.35
field-weighted impact
References
41
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.